SynthesisStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2016
Prospective randomized clinical studies involving reirradiation : Lessons learned.
Synthesis in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prospective randomized clinical studies involving reirradiation: update of a systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Pooled it
- Clinical workflow for reirradiation: national consensus recommendations on imaging, treatment planning, dose accumulation, and treatment delivery.Acta oncologica (Stockholm, Sweden) · 2025Article
- A comprehensive national audit of radiotherapy retreatment numbers, sites and indications.Acta oncologica (Stockholm, Sweden) · 2025Article
- Re-irradiation of canine non-lymphomatous nasal tumours using stereotactic radiation therapy (10 Gy x 3) for both courses: Assessment of outcome and toxicity in 11 dogs.Veterinary and comparative oncology · 2022Article
- The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.Radiation oncology (London, England) · 2020Article
- Provider decision regret-a useful method for analysis of palliative thoracic re-irradiation for lung cancer?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Article
- Plasma-based biomaterials for the treatment of cutaneous radiation injury.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2019Article
- Article
- Article
- Cancer risk assessment in modern radiotherapy workflow with medical big data.Cancer management and research · 2018Review
- Preserving the legacy of reirradiation: A narrative review of historical publications.Advances in radiation oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReirradiation is a potentially useful option for many patients with recurrent cancer. The purpose of this study was to review all recently published randomized trials in order to identify methodological strengths and weaknesses, comment on the results, clinical implications and open questions, and give advice for the planning of future trials. MATERIALS AND
methodsSystematic review of trials published between 2000 and 2015 (databases searched were PubMed, Scopus and Web of Science).
resultsWe reviewed 9 trials, most of which addressed reirradiation of head and neck tumours. The median number of patients was 69. Trial design, primary endpoint and statistical hypotheses varied widely. The results contribute mainly to decision making for reirradiation of nasopharynx cancer and bone metastases. The trials with relatively long median follow-up confirm that serious toxicity remains a concern after high cumulative total doses.
conclusionMulti-institutional collaboration is encouraged to complete sufficiently large trials. Despite a paucity of large randomized studies, reirradiation has been adopted in different clinical scenarios by many institutions. Typically, the patients have been assessed by multidisciplinary tumour boards and advanced technologies are used to create highly conformal dose distributions.
Indexed as
Identifiers
27534408What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.